辛伐他汀对动脉瘤性蛛网膜下腔出血患者疗效的Meta分析被引量：4

Simvastatin for patients with aneurysmal subarachnoid hemorrhage：a Meta-analysis

导出

摘要目的系统评价辛伐他汀治疗动脉瘤性蛛网膜下腔出血患者的临床效果。方法计算机检索辛伐他汀用于动脉瘤性蛛网膜下腔出血的随机对照研究，检索时间从数据库各建库时间到2015年10月。由南京医科大学附属淮安第一医院神经内科的2位研究者独立评价纳入研究的质量、提取数据，统计分析采用RevMan5．1软件进行。结果纳入5项研究，共951例患者。Mere分析结果显示：辛伐他汀不能降低脑血管痉挛[相对危险度（RR）：1．26，95％置信区间（CI）：0．9-1．75，P=0．170]、迟发性脑缺血（RR=1．06，95％CI：0．88-1．26，P=-0．000）、不良预后（RR=1．05，95％CI：0．90-1．23，P=-0．540）发生率及死亡率（RR=0．95，95％CI：0．62～1．44，P=-0．800）。结论辛伐他汀不能够预防动脉瘤性蛛网膜下腔出血后血管痉挛、迟发性脑缺血及改善预后。 Objective To evaluate the effectiveness ofsimvastatin for patients with aneurysmal subaraehnoid hemorrhage. Methods Systematic literature retrieval was carried out to obtain randomized controlled trials of simvastatin in patients with aneurysrnal subarachnoid hemorrhage before October 2015. Methodological quality assessment and data collection were performed by two individual reviewers. A Meta-analysis was performed by RevMan 5.1 software. Results Five studies, a total of 951 patients, were included. Meta-analysis showed that simvastatin could not reduce cerebral vasospasm （RR=1.26, 95% confidence interval [95%CI]： 0.9-1.75, P=0.170）, delayed cerebral ischemia （RR=1.06, 95%CI： 0.88-1.26, P=-0.000）, poor outcome （RR=1.05, 95%CI： 0.90-1.23, P=0.540）, or mortality （RR=0.95, 95%CI： 0.62-1.44, P=0.800）. Conclusion Simvastatin could not prevent cerebral vasospasm and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage, and could not improve the prognosis.

作者郭永涛李明超王丽君程谦涛

机构地区南京医科大学附属淮安第一医院神经内科

出处《中华神经医学杂志》 CAS CSCD 北大核心 2016年第12期1235-1239,共5页 Chinese Journal of Neuromedicine

关键词辛伐他汀动脉瘤性蛛网膜下腔出血 META分析 Simvastatin Aneurysmal subaraehnoid hemorrhage Meta- analysis

分类号 R743.35 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献2

1王青松,李钢.蛛网膜下腔出血后脑血管痉挛发病机制的研究新进展[J].中华神经医学杂志,2013,12(4):422-425. 被引量：32
2董梅.他汀类药物临床应用的多效性[J].实用医学杂志,2013,29(19):3262-3264. 被引量：11

二级参考文献32

1Komotar RJ, Schmidt JM, Starke RM, et al. Resuscitation and critical care of poor-grade subarachnoid hemorrhage [J]. Neurosurgery, 2009, 64(3): 397-410.
2lbrahim GM, Vachhrajani S, Ilodigwe D, et al. Method ofaneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage[J]. Neurosurgery, 2012, 70(1 ): 102-109.
3lshiguro M, Murakami K, Link T, et al. Acute and chronic effects of oxyhemoglobin on voltage-dependent ion channels in cerebral arteries[J]. Acta Neurochir Suppl, 2008, 104: 99-102.
4Silva G, Jeney V, Chora A, et al. Oxidized hemoglobin is an endogenous proinflammatory agonist that targets vascular endothelial cells[J]. J Biol Chem, 2009, 284(43): 29582-29595.
5WindmuUer O, Lindauer U, Foddis M, et al. Ion changes in spreading ischaemia induce rat middle cerebral artery constriction in the absence of NO[J]. Brain, 2005, 128(Pt 9): 2042-2051.
6Larsen R, Gouveia Z, Soares MP, et al. Heme Cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases[J]. Front Pharmaeol, 2012, 3: 77.
7Shimada Y, Tsunoda H, Zang L, et al. Synergistic induction of heme oxygenase-1 by nicaraven after subarachnoid hemorrhage to prevent delayed cerebral vasospasm[J]. Eur J Pharmacol, 2009, 620 (1-3): 16-20.
8Pyne-Geithman GJ, Nair SG, Caudell DN, et al. PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF [J]. Front Biosci, 2008, 13: 1526-1534.
9Hou S, Xu R, Clark JF, et al. Bilirubin oxidation end products directly alter K^+ channels important in the regulation of vascular tone[J]. J Cereb Blood Flow Metab, 2011, 31(1): 102-112.
10Zhang ZW, Yanamoto H, Nagata I, et al. Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: proposed growth factor explanation of cerebral vasospasm [J]. Neurosurgery, 2010, 66(4): 728-735.